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Abstract
Extracellular nucleotides can elicit a wide array of cellular responses by binding to specific purinergic receptors. The
level of ectonucleotides is dynamically controlled by their release from cells, synthesis by ectonucleoside
diphosphokinases and ectoadenylate kinases, and hydrolysis by ectonucleotidases. One of the four structurally unrelated
families of ectonucleotidases is represented by the NPP-type ectophosphodiesterases. Three of the seven members of the
NPP family, namely NPP1Y3, are known to hydrolyze nucleotides. The enzymatic action of NPP1Y3 (in)directly results in
the termination of nucleotide signaling, the salvage of nucleotides and/or the generation of new messengers like ADP,
adenosine or pyrophosphate. NPP2 is unique in that it hydrolyzes both nucleotides and lysophospholipids and, thereby,
generates products that could synergistically promote cell motility. We review here the enzymatic properties of NPPs and
analyze current evidence that links their nucleotide-hydrolyzing capability to epithelial and neural functions, the immune
response and cell motility.
Abbreviations: Ado –adenosine; ADP–adenosine 50 diphosphate; AMP–adenosine 50 monophosphate; ApnA–diadeno-
sine polyphosphate; ATP–adenosine 50 triphosphate; CSF–cerebrospinal fluid; E-NTPDases–ectonucleoside triphosphate
diphosphohydrolases; GPC–glycerophosphorylcholine; LPA–lysophosphatidic acid; LPC–lysophosphatidyl choline;
MCC–mucociliary clearing; NAD
+–nicotinamide adenine dinucleotide; NMN–nicotinamide mononucleotide; NPP–
nucleotide pyrophosphatase/phosphodiesterase; Pi–inorganic phosphate; PPi–pyrophosphate; SM–sphingomyelin; SMB–
somatomedin-B like domain; S-S bridges–disulfide bridges; UDP-glucose–uridine diphosphate glucose
Introduction
Extracellular nucleotides function as autocrine or paracrine
signaling molecules. Their binding to P2 purinergic
receptors leads to both short-term and long-term effects
[1]. Short-term effects, like neurotransmission and hor-
mone secretion, are mediated by the ionotropic P2X
receptors that bind mainly ATP, while long-term effects,
including cell proliferation, differentiation and migration,
occur via the metabotropic G-protein coupled P2Y recep-
tors that interact with a broader range of nucleotides [2Y5].
In keeping with their importance in cell signaling, the
extracellular concentration of nucleotides is tightly regu-
lated. Nucleotides can be released from cells primarily by
exocytosis or selective transport through the plasma
membrane [1, 6], but they can also be generated extracel-
lularly by nucleoside diphosphokinase and adenylate
kinase activities [7Y9] (Figure 1). There are four major
families of ectonucleotidases, namely E-NTPDases (ecto-
nucleoside triphosphate diphosphohydrolases), alkaline
phosphatases, NPP-type ectophosphodiesterases and the
50-nucleotidase [10]. Often these ectonucleotidases work in
concert or consecutively (Figure 1). ATP, for instance, can
be degraded in one step to either ADP or AMP by E-
NTPDase or NPP isoenzymes. ADP can be further
hydrolyzed to AMP by E-NTPDases and NPPs, and AMP
is converted to adenosine by alkaline phosphatases or the
50-nucleotidase. This sequential degradation mechanism
not only terminates ATP signaling but also generates
intermediates with distinct signaling properties. Thus,
ADP selectively interacts with P2 receptor subtypes and
is the principal platelet recruiting factor [11, 12], while
adenosine, acting through P1 receptors, plays a major role
in the regulation of blood flow and the immune response
[13Y15]. The relative contribution of the distinct ectonu-
cleotidase species to the modulation of purinergic signaling
may depend on differential tissue and cell distribution,
regulation of expression, targeting to specific membrane
domains, but also on substrate availability and substrate
preference. For example, the localization of NTPDase1 and
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combined with their substrate preference, may have direct
implications for the control of platelet activation and
coagulation responses in vivo [16, 17]. The former
ectonucleotidase metabolizes both ATP and ADP while
the latter acts primarily as an ATP phosphohydrolase.
The family of NPPs (nucleotide pyrophosphatases/
phosphodiesterases) consists of seven members, numbered
according to their order of cloning (Figure 2). Only NPP1-
3, which have a common ancestor, have been implicated in
the hydrolysis of nucleotides [10, 18, 19], while NPP6Y7
are only known to hydrolyze phosphodiester bonds in
lysophospholipids or other choline phosphodiesters
[20Y22]. Remarkably, NPP2 acts on both nucleotides and
lysophospholipids [23, 24]. Established nucleotide(-de-
rived) substrates of NPP1Y3 include ATP, diadenosine
polyphosphates (ApnA), UDP-glucose, NAD
+ and 30-
phosphoadenosine-50-phosphosulfate (Figure 2). In vitro,
NPP isoenzymes have an alkaline optimum pH, but the
physiological relevance of this property has not been
explored.
Except for NPP2, all NPPs are single-span transmem-
brane proteins. NPP1 and NPP3 have a type-II orientation,
with their N-terminus facing the cytosol, while NPP4Y7
Figure 1. NPPs are part of the extracellular nucleotide-metabolizing network. The concentration of nucleotides in the extracellular milieu is the net
result of the release of nucleotides from cells, their synthesis by nucleoside diphosphokinases and adenylate kinases, and their hydrolysis by
ectonucleotidases. The examples shown here apply to ATP, the prototype extracellular nucleotide. Members of the E-NTDPase family, also known as
apyrases, generally act as ATP diphosphohydrolases and hydrolyze ATP to ADP + Pi, and ADP to AMP + Pi, or ATP directly to AMP + 2Pi. Individual
members however display substrate preference. For instance, E-NTPDase-1 metabolizes equally well ATP and ADP, while E-NTPDase-2 prefers ATP as
a substrate. ATP can be regenerated from ADP by nucleoside diphosphokinase or adenylate kinase. NPPs, at least NPP1-3, have a nucleotide
pyrophosphatase activity and metabolize ATP directly to ADP + Pi or to AMP + PPi. The hydrolysis of AMP to adenosine by 50-nucleotidase/CD73
completes the dephosphorylation pathway of ATP. Adenosine can be taken up by cells such as lymphocytes and be re-used for intracellular nucleotide
synthesis (nucleotide salvage). Several ectonucleotide species can be expressed by a given cell type, but the relative abundance, sorting to specific
membrane domains and substrate availability are ultimately responsible for the net outcome of the nucleotide metabolism at the cell surface.
Figure 2. The phylogenetic tree of the NPP-family and some key substrates. Protein sequences for the human isoforms were retrieved from Genbank
and aligned with CLUSTAL W. Accession numbers are: hNPP1, P22413; hNPP2, NP_006200.2; hNPP3, NP_005012.1; hNPP4, AAH18054.1; hNPP5,
CAB56566.1; hNPP6, NP_699174.1; hNPP7, AAH41453.2. Representative nucleotide and/or lipid substrates are shown for each NPP isozyme. NPP1-3
have a common ancestor, and are the only known NPPs capable of hydrolyzing nucleotides. The overall aminoacid identity for the human isoenzymes, as
obtained by Blast-2 sequence analysis at the NCBI site, is 41% (NPP1YNPP2), 52% (NPP1YNPP3) and 40% (NPP2YNPP3). LPC Lysophosphatidylcho-
line, GPC glycerophosporylcholine, SM sphingomyelin.
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N-terminus facing the extracellular milieu [18, 20Y22]
(Figure 3). This prediction is supported experimentally
for NPP6 and NPP7. Thus, truncated forms of NPP6 or
NPP7 lacking the C-terminal putative transmembrane
domain are not retained at the plasma membrane and are
secreted [22, 25]. In addition, a soluble form of NPP7 is
released from the plasma membrane by trypsin, which acts
on tryptic arginine site(s) located upstream of the trans-
membrane domain. Soluble forms have also been identified
for NPP1, NPP3 and NPP6, but the mechanisms for their
generation remains to be elucidated [22, 26Y29]. NPP2 is
synthesized as a pre-pro-enzyme and only exists as a
secreted protein [30].
Our understanding of the structural and functional
diversity of NPPs has increased considerably in the last
few years. This review deals primarily with the domain
structure and enzymatic properties of NPPs, and with their
putative role in the modulation of purinergic signaling, in
particular in relation to epithelial and neural functions, the
immune response and cell motility. The reader can find
complementary information on NPPs in other recent
reviews [31, 32].
Domain structure and catalytic properties of NPPs
NPPs are modular proteins (Figure 3). In addition to a
catalytic domain they also contain subcellular targeting or
anchoring domains as well as regulatory domains.
The catalytic domain: The NPP signature
All NPPs have a catalytic domain of about 400 residues
that shows up to 60% identity at the amino acid level
between the different human isoforms. This catalytic
domain is predicted to adopt a fold similar to that of
alkaline phosphatases, phosphopentomutases and cofactor-
independent phosphoglycerate mutases, which all belong to
the superfamily of phospho-/sulfo-coordinating metalloen-
zymes [33, 34]. Also, the residues that coordinate two
metals in the catalytic site of alkaline phosphatases and
their spatial arrangement towards the catalytic site, are
conserved in NPPs. Furthermore, the reaction mechanism
of NPPs appears to be similar to that of the other phospho-/
sulfo-coordinating metalloenzymes and involves a two-step
mechanism [18]. In the first step, the catalytic-site threo-
nine/serine forms an intermediate with a phosphate group
Figure 3. Domain structure and subcellular localisation of NPPs. Except for NPP2, which is secreted in the extracellular medium, NPP ectoenzymes are
single-span membrane proteins with type-II (NPP1 and NPP3) or type-I orientation (NPP4Y7). In all cases, the bulk of the protein lies outside the cell, with
only short fragments facing the cytosol. Soluble NPP1 can be generated by cleavage of the membrane-associated form (arrow). The intracellular domains
of NPP1 and NPP3 contain determinants for targeting to the basolateral or apical side of the plasma membrane, respectively. The common structural
element of NPPs is the catalytic domain. Aminoacid identity of the catalytic domain, as obtained by Blast-2 sequence analysis of the human isoenzymes
at the NCBI site is between 24% (NPP2YNPP6) and 60% (NPP1YNPP3). The position of the threonine/serine that mediates the formation of the catalytic
intermediate is marked with white circles. The nuclease-like domain and the two somatomedin B-like domains (SMB1 and SMB2) are found only in
NPP1Y3.
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water molecule is used to regenerate the catalytic-site
threonine/serine and to release the phosphorylated product.
For example, ATP is hydrolyzed into either AMP + PPi or
ADP + Pi, via an AMP- or phosphate-bound intermediate,
respectively, depending on how the substrate approaches
the catalytic site [18].
The N-terminus: Signal peptide or signal anchor?
The N-terminal 21Y76 residues harbour the determinants
for the subcellular localization of human NPPs. In NPP1
and NPP3 this region functions as a signal anchor, ensuring
a type-II orientation across the membrane, with the N-
terminus facing the cytosol. In the polarized epithelial
cells, NPP1 and NPP3 are expressed at different sides of
the plasma membrane. A di-leucine motif in the intracel-
lular domain targets NPP1 to the basolateral membrane
[35]. The N-terminus of NPP3 does not contain this motif
and is therefore targeted apically, in part after it transiently
reaches the basolateral area [36]. The first 27 residues of
NPP2 function as a signal peptide that is removed co-
translationally by the signal peptidase in the endoplasmic
reticulum. The resulting soluble pro-NPP2 is further
cleaved by furin-type proteases along the secretory path-
way to generate the mature, fully active NPP2 [30]. The
N-terminus of NPP6Y7 comprising about 20 residues
functions as a signal peptide that is cleaved co-translation-
ally. However, NPP6Y7 have a C-terminal transmembrane
domain, which accounts for their type-I transmembrane
orientation, leaving the bulk of the protein extracellularly.
The somatomedin-B like domains of NPP1Y3: An elusive
function
Two cysteine-rich somatomedin-B like domains lie be-
tween the transmembrane and the catalytic domain of
NPP1Y3. One suggested function has been that of a Fstable
stalk_ between the transmembrane and the catalytic
domains [10]. Also, NPP1 is a disulfide-linked homodimer
and cysteines in these domains have been proposed to
participate in interchain SYS bridges [18, 37]. However, the
crystal structure of the somatomedin-B domain of vitro-
nectin revealed that this domain forms a Fdisulfide-knot_,
with all eight cysteines engaged in intrachain disulphide
bonds [38]. This strongly indicates that the determinants
for the dimerization of NPP1 lie outside the somatomedin-
B like domains. Consistent with this view, secreted NPP2
does not form dimers although it also has two somatome-
din-B like domains [30]. It is therefore likely that in
NPP1Y3 these domains function as protein interaction
domains, similarly to those in vitronectin [38].
The C-terminal portion of NPP1Y3: A multifunctional,
nuclease-like domain
A stretch of about 250 residues that flanks the catalytic
domain of NPP1Y3 C-terminally shows similarities with
DNA/RNA non-specific endoribonucleases, both with
respect to its primary structure and the predicted fold
[37]. This Fnuclease-like_ domain does not endow NPPs
with a nuclease activity because the residues that are
essential for catalysis by endoribonucleases are not
conserved in NPP1Y3. However, the nuclease-like domain
does appear to contain isoform-specific determinants for
catalysis by NPP1 and NPP2, since the swapping of their
nuclease-like domain results in an inactive NPP2, while
NPP1 with the nuclease-like domain of NPP2 is fully
active [39]. The nuclease-like domain also appears to be
essential for the translocation of NPPs from the endoplas-
mic reticulum to the Golgi-apparatus, possibly because it is
required for the correct folding of NPPs [37]. Finally,
recent evidence indicates that the nuclease-like domain of
NPP2 has an anti-adhesion function and may function as a
ligand for a G-protein coupled receptor [40].
The substrate specificity of NPPs: Many unanswered
questions
NPPs can hydrolyze pyrophosphate or phosphodiester
bonds in a wide variety of substrates, although each isoform
has a well-defined substrate specificity (Figure 1). For
example, NTPs and diadenosine polyphosphates are
substrates for NPP1-3, while lysophosphatidylcholine is
only hydrolyzed by NPP2 and NPP6. Remarkably, NPP2
and NPP6 hydrolyze distinct phosphodiester bonds in
lysophosphatidylcholine, generating choline and phospho-
choline, respectively. The determinants of the substrate
specificity of NPPs are poorly understood. Clearly, the
pyrophosphate or phosphodiester bond is not the only
substrate-specifying element of NPPs. Site-directed muta-
genesis and domain swapping studies revealed that the
non-catalytic domains as well as residues near the
catalytic site control the activity and substrate specificity
of NPP1 and NPP2 [39]. The catalytic domain of NPP1
contains a GxGxxG motif that resembles part of a consensus
dinucleotide-binding motif and is essential for catalysis by
NPP1,butitdoesnotappeartobeasubstrate-specifyingmotif
[39]. Lipid-consensus motifs, similar to those found in
phospholipases D are not present in NPP2. [41]. Neverthe-
less, it cannot be excluded that NPPs contain hitherto
unrecognized nucleotide or lipid binding sites similarly to,
for example, the substrate-specifying Fpockets_ of serine
proteases.
Role of NPP1Y3 in the metabolism of extracellular
nucleotides
NPP1Y3, alone or in combination, are expressed in every
cell type that has been analyzed for their presence [18, 31].
It therefore seems likely that these NPPs fulfill a broad
range of functions. NPP isozymes may even Fmoonlight,_
in that they can fulfill multiple, apparently unrelated
functions. For example, NPP1 is not only implicated in
nucleotide metabolism but also appears to have an anti-
insulin action by a mechanism that does not require
catalytic activity [42, 43]. By far the best studied NPP
364 C. Stefan et al.function concerns the role of NPP1 in bone and soft-tissue
mineralization [44, 45], which is the subject of a separate
review in this issue. We only discuss here how NPP1Y3
contribute, as nucleotide-metabolizing enzymes, to the
epithelial and neural functions, the immune response and
cell motility.
NPP1Y3 and epithelial functions
Most epithelial cells release nucleotides, either constitu-
tively or when challenged with stimuli like mechanical
stress or hypotonicity-induced swelling. In the extracellular
environment of epithelial cells, purinergic signaling is of
prime importance for ion transport, cellYcell communica-
tion and cell migration [46Y48].
Airway epithelia
Nucleotide metabolism at the surface of human airways
has received much attention because of the critical role of
nucleotides in the protective mechanism against bacterial
and viral infections, known as mucociliary clearance
(MCC) [49Y53]. This defense mechanism involves com-
plex signaling by diadenosine polyphosphates, ATP and
adenosine, affecting overall fluid homeostasis via a control
of epithelial chloride secretion and sodium uptake. In fact,
nucleotide-based treatments combined with ecto-nucleotid-
ase inhibitors are used for the improvement of MCC in
chronic obstructive lung diseases such as cystic fibrosis.
Some efforts have been undertaken to identify the
ectonucleotidases expressed by airway epithelia. There is
good biochemical evidence for the presence of both
NTPDase-type [51] and NPP-type activities [54]i n
the airway epithelia. Transcript analysis revealed the pre-
sence of various ectonucleotidases including NTPDase2,
NTPDase3, NTPDase5 as well as NPP1Y3[ 55]. However,
not all of them may be expressed at the protein level
equally well. Importantly, human airway ectonucleotidases
are cell-associated and are predominantly apical [51].
Within the NPP family, this suggests a role for NPP3,
which is indeed targeted to the apical surface, while NPP1
is expressed at the basolateral one, and NPP2 only exists as
a secreted form. However, NPP2 might also fulfill a critical
function in the lung because the transcript level in the lung
is among the highest of all tested organs [56]. In airways an
NPP-type pyrophosphatase activity may be mainly in-
volved in regulation of signaling by diadenosine poly-
phosphates, which were recently shown to bind to P2Y
purinergic receptors distinct from those activated by ATP
[57]. Other ectonucleotidases identified in human airway
epithelia are the tissue non-specific alkaline phosphatase,
exclusively expressed at the apical surface, and 50-
nucleotidases, expressed at both apical and basolateral
sides [58].
Liver epithelia
The liver epithelial cells, i.e. hepatocytes and cholangio-
cytes, contribute to bile formation and secretion, one of the
primary functions of the liver. Bile is formed by the
parenchymal hepatocytes and is further enriched in
bicarbonate by cholangiocytes, the cells that line the bile
ducts [59, 60]. The biliary epithelium constitutively
releases ATP into the bile from a vesicular storage site,
and increase in cell volume promotes the exocytosis of
ATP through a phosphoinositide 3-kinase-dependent mech-
anism [61]. Hepatocytes, too, contribute to the biliary pool
of ATP [59]. NPP3 is the major NPP isoenzyme at the
apical membrane of both hepatocytes and cholangiocytes
[62, 63]. An apical localization in hepatocytes has also
been established for 50-nucleotidase [59]. By regulating the
breakdown of biliary ATP these nucleotide-hydrolyzing
enzymes may interfere with purinergic signaling at the bile
canaliculi, and thereby modulate the process of bile
formation. In cholangiocytes, NPP3 may be one of the
major apical ectonucleotidases, consistent with the func-
tional expression of a single, dominant ATP degradation
pathway at this site [64]. By contrast, NTPDase2/CD39L1
has been identified in portal fibroblasts and appears to be
the main ectonucleotidase that indirectly controls puriner-
gic signaling at the basolateral membrane of cholangio-
cytes [65]. The role of basolateral nucleotides in bile
ductular secretion is relatively minor when compared to
that of apical nucleotides, but there is evidence that
basolateral nucleotides modulate the growth and differen-
tiation of cholangiocytes [66].
The role of NPP3 in cholangiocytes may extend beyond
the regulation of bile formation. Indeed, large amounts of
NPP3 are found in the extracellular matrix and in the
serum of chemically induced rat cholangiocarcinoma [67],
an adenocarcinoma of intrahepatic bile ducts. Neoplastic
transformation of biliary cells leads to an overexpression of
NPP3 but also to its inappropriate targeting to the
basolateral rather than to the apical side of the cholangio-
cytes. Since NPP3 can stimulate migration of cultured cells
it may also be involved in metastasis of neoplastic
cholangiocytes, by an as yet unknown mechanism [63].
NPP1 is also abundantly expressed in hepatocytes and
localizes basolaterally [63]. An enticing hypothesis is that
this pool of NPP1 controls the turnover of extracellular
ATP, which functions as a potent hepatic mitogen by
increasing immediate early gene expression in a P2-
receptor dependent manner [68]. Consistent with this
notion, the level of NPP1 is considerably decreased during
liver regeneration following 70% partial hepatectomy and
only reaches its initial level again after the major growth
phase of the liver has passed [69]. We speculate that the
transient drop in the concentration of NPP1 enables the
accumulation of extracellular ATP, needed to stimulate cell
proliferation.
Intestinal epithelia
Enterocytes constitute the major fraction of intestinal
epithelial cells and their primary function is to absorb
nutrients from the diet. Nucleotides are semi-essential or
conditionally essential nutrients [70]. Cells can synthesize
nucleotides de novo and re-use them through the nucleo-
tide salvage pathway. However, rapidly proliferating
tissues such as the intestine have an insufficient biosyn-
thetic capacity and are dependent on an exogenous supply
NPP-type phosphodiesterases in nucleotide signaling 365of nucleotides. NPP3 is the major NPP isoenzyme at the
brush border of enterocytes [62]. Given its very high
expression, combined with its co-localization with 50-
nucleotidase [71] or alkaline phosphatase, it seems likely
that these ectonucleotidases play an important role in the
digestion of dietary nucleotides and their derivatives but a
direct evidence for this contention is lacking.
NPP1Y3 and neural functions
Extracellular nucleotides, in particular ATP, have multiple
functions in the central nervous system. ATP acts as a
neurotransmitter and modulator of neurotransmitter re-
lease, but also as a trophic factor that stimulates prolifer-
ation and differentiation of neural cells [5, 72Y75].
Neurons, glial cells and endothelial cells are established
sources of extracellular purines. Initial evidence reveals
important functions for NPPs in the nervous system, at
least in part by their ability to modulate purinergic
signaling.
Within the brain, a panel of P2X receptors as well as
NPP2 and NPP3 are expressed by the choroid-plexus
epithelial cells [76Y78]. The latter cells secrete cerebrospi-
nal fluid (CSF), the major extracellular fluid in the central
nervous system. CSF provides the central nervous system
with nutrients and signaling molecules, and removes
metabolites [79]. It seems likely that NPP2/3 contribute
to the secretion of CSF by modulating purinergic signaling
[78]. In rodents NPP2 can also be detected in the CSF
itself. This pool of NPP2 possibly originates from the
choroid-plexus epithelial cells and/or from the leptome-
ningeal cells and has recently been shown to function as a
neurite retraction factor [80]. Remarkably, in humans
NPP2 is absent from the CSF of healthy persons, but is
found in the CSF from patients with multiple sclerosis [81].
NPP2 is also secreted by oligodendrocytes, the myelin
producing cells [82]. A tight correlation was noted between
the expression of NPP2 in oligodendrocytes and the initial
stages of myelination, a complex process that includes the
movement of oligodendrocytes to the sites of myelination.
NPP2 has been identified as an autocrine Fcounteradhesive_
factor and may thus be implicated in the movement of
oligodendrocytes to their target sites [82]. Surprisingly, this
function does not require the catalytic domain of NPP2 and
appears to be mediated by the nuclease-like domain, which
possibly interacts with a G-protein coupled receptor [40].
In the developing brain NPP3 is first scattered through-
out the neuroepithelium and adjacent mesenchymal tissue,
but later appears in distinct brain regions to reach the
strongest expression on meninges, ependymal layers and
choroid plexus [77]. The latter structures maintain a strong
expression of NPP3 until adulthood. NPP3 was also found
to be transiently expressed in a population of neural
progenitor cells that can differentiate into radial glial-like
cells, a subset of astrocytes and ependymal cells [77].
Since NPP3 is not expressed by mature astrocytes, this may
suggest an involvement of this isoenzyme in keeping their
progenitor cells dedifferentiated. Consistent with this
notion, it was reported that the expression of NPP3 in
NPP3-negative cell lines induces the expression of glial
fibrillary acidic protein, an intermediate-filament protein
specific for the cytoskeleton of astroglial cells and non-
myelin-forming Schwann cells. Interestingly, the over-
expression of NPP3 has also been associated with
increased motility and invasive properties of cultured cells
[83].
Figure 4. Role of NPP1Y3 in the metabolism of extracellular nucleotides. NPP1 and CD38 are co-expressed in T-lymphocytes. Extracellular NAD
+ is a
substrate for NPP1, a NAD
+-pyrophosphatase, as well as for CD38, a NAD
+-glycohydrolase. The coordinated expression of NPP1 and CD38 is part of a
protective mechanism against NAD
+-induced apoptosis of T cells. The hydrolysis of NAD
+ by the concerted action of NPP1, CD38 and 50-nucleotidase
also allows activated T cells to re-use the products for their own anabolic processes. At the apical membrane of hepatocytes and cholangiocytes, NPP3
hydrolyzes bile ATP and modulates purinergic signaling at these sites. Diadenosine polyphosphates (Ap3Y5A) and other nucleotides are hydrolyzed at the
apical surface of the human airways by an NPP-type pyrophosphatase. Likely candidates are NPP3 and/or NPP2.
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conditions has not been reported. However, NPP1 is the
major ectonucleotidase in the rat C6 glioma cell line [84,
85]. This cell line is morphologically similar to glioblas-
toma multiforme, the most common aggressive glioma
resistant to therapeutic interventions [86].
NPP1 and lymphocyte signaling
NPP1 is a marker of a late stage in the differentiation of
antibody-producing B cells, but its expression is not
required for the synthesis and secretion of antibodies.
Although initially believed to be lineage-specific [87], in
the meantime it has been established that low levels of
NPP1 are also found in T cells and that its expression in
these cells is increased through signaling by protein
kinases A and C, the same pathways that also up-regulate
the expression of the NAD
+ glycohydrolase CD38 [88].
The coordinated expression of NPP1 and CD38 enables the
hydrolysis of extracellular NAD
+ by activated T cells to
nicotinamide mononucleotide + AMP or to nicotinamide +
ADP-ribose, respectively (Figure 4). In doing so, NPP1 and
CD38 control the substrate availability for NAD
+-depen-
dent ADP-ribosylation by ADP-ribosyltransferases at the
cell surface. This can be seen as a protective mechanism
against apoptosis at sites of inflammation, where the
release of NAD
+ results in ADP-ribosylation and activation
of the pro-apoptotic P2X7 receptors [89, 90]. By the same
mechanism NPP1 and CD38 also provide a protection
against the ADP-ribosylating bacterial toxins, such as
cholera or C. botulinum C3 toxins, which exert their
cytotoxic effects through ADP-ribosylation of host signal-
ing molecules [91]. Both NAD
+ and its degradation
product ADP-ribose are potent inhibitors of T-cell prolif-
eration [92]. Their hydrolysis by CD38 and NPP1 is thus
expected to promote T-cell proliferation. Finally, in
combination with 50 nucleotidase, CD38 and NPP1 are
part of the nucleotide-salvage pathway [88] (Figure 4).
NPP2 and cell motility
NPP2 is secreted by various cancer cells including skin,
lung and breast cancer cells. Its tumour growth and
motility effects have been primarily attributed to its ability
to produce lysophosphatidic acid (LPA) from lysophos-
phatidylcholine (LPC) [93]. LPA binds to dedicated G-
protein-coupled receptors, LPA1Y4, and activates multiple
signaling pathways, leading to cell proliferation, cell-shape
changes and migration. These effects explain why NPP2
promotes tumour growth, angiogenesis and metastasis
(Figure 5). However, it can be envisaged that NPP2 also
promotes tumour growth by its ability to hydrolyze
nucleotides. Indeed, solid tumours are well known to
release adenine nucleotides and NPP2 can hydrolyze
ATP, which is an inhibitor of tumour-cell proliferation
[49]. Moreover, the concerted action of NPP2 and
50-nucleotidase on ATP and ADP generates adenosine, a
tumour-growth promoter and stimulator of angiogenesis
(Figure 4)[ 94Y96]. In this respect, it is also worthy of note
that the Wnt/b-catenin signaling pathway is activated in
many human tumours, resulting in an increased expression
of both NPP2 [97, 98] and 50-nucleotidase [99].
Conclusions and perspectives
The family of NPP-type ectophosphodiesterases com-
prises a versatile group of seven ecto-enzymes that
hydrolyze pyrophosphate and phosphodiester bonds in a
broad range of metabolites, yet each isozyme has a rather
narrow substrate-specificity. Only NPP1Y3 are known to
hydrolyze nucleotides and they are part of a complex
nucleotide interconversion network at the cell surface.
NPP1Y3 contribute to ectonucleotide signaling both by
removing active compounds and by generating nucleotide
metabolites with distinct signaling properties. The com-
plexity of signaling via NPPs is further increased by their
ability to hydrolyze non-nucleotide substrates. For exam-
ple, NPP2 can hydrolyze both phospholipids and nucleo-
Figure 5. Tumour growth and metastasis: Role of NPP2-catalyzed
reactions. In the extracellular milieu the tumour-motility stimulating
factor NPP2 generates LPA from LPC. LPA promotes cell proliferation,
migration and angiogenesis. In a coupled reaction with 50-nucleotidase,
NPP2 has the potential to hydrolyze ATP, which is cytotoxic for tumours,
to adenosine, a tumour-growth promoting factor and stimulator of
angiogenesis. The expression of both NPP2 and 50-nucleotidase is
increased by the Wnt/b-catenin pathway, which is activated in many
cancers.
NPP-type phosphodiesterases in nucleotide signaling 367tides and the generated products have the potential of
acting antagonistically or synergistically. A surprising
finding has been that NPP1 and NPP2 have also functions
that do not require catalytic activity. This can imply that
NPPs moonlight, although it cannot be ruled out that their
noncatalytic functions are somehow connected to their
catalytic functions.
Much remains to be learned about the enzymatic
properties, regulation and functional diversity of NPPs. A
lot is expected from the phenotyping of knockout models
for each NPP isoenzyme. Also, the availability of isoen-
zyme-specific NPP inhibitors would be of great help to
study their function. The latter also have therapeutic
potential as they hold great promises for the treatment of
devastating diseases like cystic fibrosis and bone-mineral-
ization pathologies.
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